Adcetris

Adcetris Indications/Uses

brentuximab vedotin

Manufacturer:

Takeda

Distributor:

DKSH
Full Prescribing Info
Indications/Uses
Previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy: ADCETRIS is indicated for the frontline treatment of adult patients with previously untreated CD30+ advanced cHL in combination with doxorubicin, vinblastine and dacarbazine (AVD) (see Pharmacology: Pharmacodynamics under Actions).
Hodgkin lymphoma (HL) consolidation: ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT) (see Pharmacology: Pharmacodynamics under Actions).
Relapsed or refractory Hodgkin lymphoma (HL): ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): Following autologous stem cell transplant (ASCT) or; following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
Frontline systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), in combination with chemotherapy: ADCETRIS is indicated for the treatment of patients with CD30-expressing previously untreated peripheral T-cell lymphoma (PTCL) in combination with chemotherapy.
Relapsed or refractory systemic anaplastic large cell lymphoma (sALCL):
ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
CD30+ cutaneous T-cell lymphoma (CTCL): ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (see Pharmacology: Pharmacodynamics under Actions).
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in